Online citations, reference lists, and bibliographies.
← Back to Search

Psychological Profile And Quality Of Life In Patients With Acromegaly In Greece. Is There Any Difference With Other Chronic Diseases?

P. Anagnostis, Z. Efstathiadou, M. Charizopoulou, D. Selalmatzidou, Eleni Karathanasi, M. Poulasouchidou, M. Kita
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Several studies have shown that acromegaly is associated with increased psychological morbidity. However, it is not known whether this is attributed to acromegaly per se or to its chronicity as a debilitating disease affecting quality of life (QoL). The aim of this study was to assess psychological profile in acromegalics compared with those suffering from other serious chronic diseases and healthy controls. Secondary end points were QoL assessment and its association with mood disturbances. Comparative, cross-sectional study conducted in Northern Greece (2011–2012). The Greek versions of the Profile of Mood States (POMS) and AcroQoL questionnaires were used to assess psychological status and QoL, respectively. Forty acromegalics, 40 age- and sex-matched people with other chronic diseases and 80 healthy controls were included. No significant differences were identified between acromegalics and those suffering from other chronic diseases, regarding tension, anger, depression, confusion, fatigue and vigor. Compared with healthy controls, acromegalics suffered more from depression and anger, which remained significant after controlling for age, gender and marital status (p = 0.003 and p = 0.048, respectively). Negative predictors were female gender, macroadenomas and radiotherapy. AcroQoL scores were negatively associated with POMS subscales. Males had better QoL than females. Other than a negative association between AcroQoL-relationships subscale and disease duration, no association with other parameters was observed. Acromegaly has a negative impact on psychological status, which is worse than that of general population, but comparable to other chronic diseases. Mood disturbances are associated with impaired QoL, mainly in females and those with longer disease duration.
This paper references
10.1046/j.1365-2265.2002.01597.x
Acromegaly Quality of Life Questionnaire (ACROQOL) a new health‐related quality of life questionnaire for patients with acromegaly: development and psychometric properties
S. Webb (2002)
10.1038/sj.npp.1300298
The Somatostatin Analogue Octreotide Impairs Sleep and Decreases EEG Sigma Power in Young Male Subjects
M. Ziegenbein (2004)
10.1530/EJE-08-0896
Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls.
C. Sievers (2009)
10.1111/j.1365-2265.2007.03169.x
Previous radiotherapy negatively influences quality of life during 4 years of follow‐up in patients cured from acromegaly
A. A. van der Klaauw (2008)
The effect of octreotide treatment on somatic and psychological symptoms of acromegaly.
M. Ruchała (2010)
Spanish AcroQol Study Group , Validity and clinical applicability of the acromegaly quality of life questionnaire , AcroQoL : a 6 - month prospective study
X. Badia Webb (2002)
10.3275/7333
Predictive factors for neurocognitive function and Quality of Life after surgical treatment for Cushing’s disease and acromegaly
T. Psaras (2011)
10.1210/jc.2009-2670
A consensus on criteria for cure of acromegaly.
A. Giustina (2010)
10.1007/s11102-008-0143-1
Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study
C. Sievers (2008)
10.1111/j.1742-1241.2011.02682.x
Acromegaly: presentation, morbidity and treatment outcomes at a single centre
P. Anagnostis (2011)
10.1530/EJE-11-0853
Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.
M. Postma (2012)
10.1210/jc.2010-0394
Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly.
J. Leon-Carrion (2010)
10.1055/s-0030-1267991
Non-functioning pituitary adenomas: a single center experience.
P. Anagnostis (2011)
10.1007/s11102-012-0447-z
Diagnostic delay is associated with psychosocial impairment in acromegaly
S. Siegel (2012)
10.1111/j.1365-2265.2005.02307.x
Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)
R. Trepp (2005)
10.1212/WNL.0b013e318283bb0a
Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline
A. Peiffer (2013)
10.1007/s12020-008-9112-8
Psychosocial morbidity in acromegaly: a study from India
S. Mattoo (2008)
10.1192/BJP.139.5.467
Acromegaly and depression.
A. Margo (1981)
10.1007/s11136-011-9846-2
Validation of POMS questionnaire in postmenopausal women
K. Wyrwich (2011)
10.1530/EJE-07-0697
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
M. Matta (2008)
10.1111/j.1365-2265.2009.03626.x
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosed
Tirissa J. Reid (2010)
10.1007/BF03346555
Short- and long-term changes of quality of life in patients with acromegaly: Results from a prospective study
C. Sardella (2010)
10.1210/jc.2008-2671
Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly.
T. Wexler (2009)
10.1210/JC.2006-0676
Quality of life in treated patients with acromegaly.
R. Kauppinen-Mäkelin (2006)
10.1007/s12020-013-0106-9
Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study
Chris G. Yedinak (2013)
10.1002/PON.564
A POMS short form for cancer patients: psychometric and structural evaluation
F. Baker (2002)
Manual for the Profile of Mood States
D. Mcnair (1971)
10.5402/2012/675310
Long-Term Health-Related Quality of Life of Surgically Treated Pituitary Adenoma Patients: A Descriptive Study
A. Raappana (2012)
10.1016/j.ghir.2010.02.003
Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.
M. J. E. Wassenaar (2010)
10.1530/EJE.1.02292
Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
Shih-Che Hua (2006)
10.1055/s-0032-1323765
Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly.
P. Anagnostis (2013)
10.1530/EJE-07-0838
Impact of musculoskeletal disease on quality of life in long-standing acromegaly.
A. Miller (2008)
10.3275/7045
Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy.
N. Maric (2010)
10.1210/ER.2004-0022
The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults.
L. Woodhouse (2006)
10.1210/JC.2004-0669
Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.
N. Biermasz (2004)
10.1159/000095532
Quality of Life in Acromegaly
S. Webb (2006)
10.1530/EJE.1.02214
Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.
S. Webb (2006)
10.1159/000375451
Quality of Life in Acromegaly
S. Webb (2015)



This paper is referenced by
10.3389/fendo.2014.00229
Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life
V. Geraedts (2015)
10.1210/er.2018-00115
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.
M. Gadelha (2019)
10.1007/s11102-018-0887-1
Cognitive-behavioral therapy improves the quality of life of patients with acromegaly
Lia Silvia Kunzler (2018)
10.1007/s11102-015-0665-2
The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL
K. Yoshida (2015)
10.3389/fendo.2017.00040
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
V. Geraedts (2017)
10.25121/PNM.2017.30.12.651
Evaluation of factors affecting quality of life in acromegaly
S. Zgliczyński (2017)
10.1530/EJE-20-0019
Prolonged Diagnostic Delay in Acromegaly is Associated with Increased Morbidity and Mortality.
D. Esposito (2020)
10.1016/j.ghir.2014.12.003
Acromegaly and aging: a comparative cross-sectional study.
E. Hatipoğlu (2015)
10.1007/978-3-319-39901-0_7
Dealing with Difference: Using the Osteobiographies of a Woman with Leprosy and a Woman with Gigantism from Medieval Poland to Identify Practices of Care
Magdalena Domicela Matczak (2017)
10.5603/EP.a2017.0044
Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity?
D. Szcześniak (2017)
10.1016/j.tem.2014.10.005
Growth hormone deficiency in treated acromegaly
G. Mazziotti (2015)
10.4103/ijem.ijem_401_20
Health-related Quality of Life in Acromegaly Patients: Results from Generic and Disease-specific Questionnaires
B. D. A. Oliveira (2020)
10.1016/j.beem.2017.03.002
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.
A. Formenti (2017)
10.1155/2018/6135080
Higher Income and Integration into the Workforce Are the Main Factors Associated with Quality of Life in Acromegalic Patients in Northeastern Brazil
Adriana Maria GuimarãesSá (2018)
Acromegaly: current therapies benefits and burdens
Chris G. Yedinak (2018)
10.15406/EMIJ.2017.04.00074
Quality of life in acromegaly and the association with the clinical parameters of the disease
Dimitrios Kaldrymidis (2017)
10.1007/s10143-019-01134-z
Pituitary adenomas and neuropsychological status: a systematic literature review
Marta Pertichetti (2019)
Depresja, lęk oraz stres u chorych na akromegalię — obserwacje własne
Joanna Malicka (2015)
10.1530/eje-19-1023
MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly.
N. Lenders (2020)
10.1007/s12020-014-0521-6
Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire
S. Vandeva (2014)
Semantic Scholar Logo Some data provided by SemanticScholar